Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.
Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member ...
Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...
GlobalData on MSN12d
Tizona’s TTX-080 colorectal cancer trial expands with new armsTizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, HLA-G, in patients with biomarker-defined ...
Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing ...
"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...
Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative and HER2-positive breast cancer. The study highlights the role of ...
Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer ... significant overall-survival improvement in patients with early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback